Answers are grounded in this paper and cite their sources.
in Europe, is a new therapeutically available serotype among the botulinum toxin family. During the last years several data have been reported in literature investigating its efficacy and safety, as well as defining the dosing and application regiments of BoNT-B in the treatment of hyperhidrosis. Moreover, recent studies have been examining its safety profile, which may be different from those known about BoNT-A. The aim of this review is to provide information about what is currently known about BoNT-B in regards to the treatment of focal hyperhidrosis.
No takes yet. Share an insight, caveat, or question.
Campanati et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: